Morningstar

CRISPR Therapeutics AG CRSP

Morningstar Rating
Unlock
Stock XNAS Rating as of
$45.71 +0.13 (0.29%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Positive Outlook for Crispr Therapeutics Thanks to Blockbuster Potential of Casgevy

Rachel Elfman

Crispr Therapeutics is a clinical-stage gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced short palindromic repeats (Crispr)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. Crispr's emerging technology has led to a new class of therapies, which are well suited for targeting rare diseases or other disorders that are caused by genetic mutations.

Read Full Report

Price vs Fair Value

View History
CRSP is trading at a 226% premium.
Price
$45.70
Fair Value
$985.00
Uncertainty
Very High
1-Star Price
$713.71
5-Star Price
$67.70
Economic Moat
Vbbss
Capital Allocation
Wgkbxzlpn

Bulls Say, Bears Say

Bulls

Partnerships allow Crispr Therapeutics to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs.

Bears

Crispr Therapeutics’ pipeline is largely in the early stages of development and years away from potentially receiving approval.

Show More

News

View All

Trading Information

Previous Close Price
$45.58
Day Range
$44.83–45.99
52-Week Range
$37.55–91.10
Bid/Ask
$45.50 / $46.50
Market Cap
$3.89 Bil
Volume/Avg
927,441 / 1.2 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
18.61
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
407
Website
https://www.crisprtx.com

Competitors

Valuation

View More
Metric
CRSP
MRNA
VRTX
Price/Earnings (Normalized)
 ——26.49
Price/Book Value
 1.962.078.07
Price/Sales
 18.614.8311.60
Price/Cash Flow
 ———
Price/Earnings
CRSP
MRNA
VRTX

Financial Strength

Metric
CRSP
MRNA
VRTX
Quick Ratio
 0.003.772.10
Current Ratio
 15.734.092.52
Interest Coverage
 —−169.39−10.25
Quick Ratio
CRSP
MRNA
VRTX

Profitability

Metric
CRSP
MRNA
VRTX
Return on Assets (Normalized)
 −8.47%−29.83%0.42%
Return on Equity (Normalized)
 −10.08%−39.97%0.55%
Return on Invested Capital (Normalized)
 −9.15%−38.74%−2.40%
Return on Assets
CRSP
MRNA
VRTX

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk AS ADR
NVO
RzhbjdjkrSzr$518.0 Bil
 Vertex Pharmaceuticals Inc
VRTX
KsrhbkxzXxkxh$119.3 Bil
 Regeneron Pharmaceuticals Inc
REGN
ZrkzfllvNknrvt$114.7 Bil
 Alnylam Pharmaceuticals Inc
ALNY
XnkrtrlcvNwzcdny$34.9 Bil
 argenx SE ADR
ARGX
JvdtspfynSyrr$32.8 Bil
 BioNTech SE ADR
BNTX
XjmfhfbrRhpsc$28.3 Bil
 Moderna Inc
MRNA
XwcdcgwLxlf$24.3 Bil
 United Therapeutics Corp
UTHR
PcsbvsncVwlcc$15.7 Bil
 Biomarin Pharmaceutical Inc
BMRN
JpqkmsqdkVqdjpw$13.3 Bil
 Incyte Corp
INCY
KxgtjjvskVtwnjtl$13.0 Bil

Sponsor Center